Shares of Quantum BioPharma (NASDAQ: QNTM) surged +10.8% to $4.30 on September 24, defying a weak biotech tape, after its licensee Unbuzzd Wellness named serial entrepreneur Michael "Zappy" Zapolin as CEO. The move signals an acceleration toward a public listing and U.S. product launch — but the gap between ambition and revenue remains vast for a company with essentially no sales.
A Wall Street Veteran Gets the Keys — and a Big To-Do List. Unbuzzd makes a beverage designed to speed up the body's processing of alcohol, reduce hangover symptoms, and restore mental clarity.
Zapolin's mandate includes financing, listing Unbuzzd on a stock exchange, and executing a nationwide U.S. marketing rollout. He began his career as one of the youngest Vice Presidents at Bear Stearns and later built and flipped internet brands like Beer.com and Diamond.com. He also co-founded KetaMD, a ketamine telemedicine company acquired by Braxia Scientific in 2022. That capital-markets résumé is precisely why the market reacted: investors are betting he can actually raise the money and get the product on shelves.
The IPO Clock Is Ticking — Next Quarter. Unbuzzd expects its transition to a public listing to become effective next quarter.
Former CEO Richard Buzbuzian is assisting with the transition. For QNTM shareholders, a separately listed Unbuzzd could unlock visible value from the licensing arrangement rather than leaving it buried inside Quantum's balance sheet.
Follow the Royalties — Quantum's Real Stake. Quantum held 19.48% of Unbuzzd as of June 30, 2026. Its agreement provides a 7% royalty on sales until payments to Quantum reach $250 million, then 3% in perpetuity. That sounds lucrative on paper, but Quantum's revenue is currently less than $1 million , and the company has less than one year of cash runway based on its free-cash-flow trend of roughly negative $5.6 million.
Shareholders have been substantially diluted in the past year, with a roughly 110% increase in shares outstanding. Royalty income is meaningless until bottles are selling nationwide — and no timeline for first material sales has been disclosed.
Clinical Data Looks Promising but the Market Is Crowded. In a placebo-controlled trial, blood-alcohol levels dropped more than 40% faster within 30 minutes for participants who consumed the product, and headache severity was 67% lower at four hours.
Roughly 70% of Americans say they actively seek health benefits from beverages. But functional drinks are a brutally competitive category, and success depends on navigating regulatory hurdles and maintaining a competitive edge in a crowded space.
At roughly $30 million in market cap, QNTM remains a speculative micro-cap whose near-term fate hinges on whether Zapolin can convert a promising clinical story into shelf space — and cash flow.